On Oct 30, major Wall Street analysts update their ratings for $AtriCure (ATRC.US)$, with price targets ranging from $36 to $60.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $35 to $40.
Oppenheimer analyst Suraj Kalia maintains with a buy rating, and adjusts the target price from $32 to $36.
Needham analyst Michael Matson maintains with a buy rating, and adjusts the target price from $34 to $40.
BTIG analyst Marie Thibault maintains with a buy rating, and maintains the target price at $53.
CCORF analyst William Plovanic maintains with a buy rating, and adjusts the target price from $49 to $53.
Furthermore, according to the comprehensive report, the opinions of $AtriCure (ATRC.US)$'s main analysts recently are as follows:
AtriCure delivered a compelling quarter, surpassing expectations not just on the surface but also in underlying performance. Despite potential impacts from PFA, the MIS Ablation segment's performance does not hinder the company's projection of sustained mid-teens growth. AtriCure continues to focus on enhancing profitability, with anticipation of positive cash flow by FY25.
The firm recognizes AtriCure's Q3 revenues of $116M as marginally surpassing the anticipated figures. The forecasted revenues stood at $113M by the firm and $112M by the consensus. The analyst maintains a positive perspective, noting that AtriCure's current valuation is approximately 2.7 times its FY25 sales, in contrast to its small-cap MedTech peer group, which trades at about 3.7 times.
Here are the latest investment ratings and price targets for $AtriCure (ATRC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月30日，多家華爾街大行更新了$AtriCure (ATRC.US)$的評級，目標價介於36美元至60美元。
瑞士銀行分析師Danielle Antalffy維持買入評級，並將目標價從35美元上調至40美元。
奧本海默控股分析師Suraj Kalia維持買入評級，並將目標價從32美元上調至36美元。
Needham分析師Michael Matson維持買入評級，並將目標價從34美元上調至40美元。
BTIG分析師Marie Thibault維持買入評級，維持目標價53美元。
CCORF分析師William Plovanic維持買入評級，並將目標價從49美元上調至53美元。
此外，綜合報道，$AtriCure (ATRC.US)$近期主要分析師觀點如下：
AtriCure交出了一個引人注目的季度報告，不僅在表面上超出了預期，而且在基本表現上也如此。儘管受PFA的可能影響，MIS消融部門的表現並沒有阻礙公司對持續中等增長的預測。AtriCure繼續專注於提高盈利能力，預計到FY25年會出現正現金流。
該公司認可AtriCure第三季度的11600萬美元營收略微超過了預期的數字。公司預測的營收爲11300萬美元，共識爲11200萬美元。分析師保持積極態度，指出AtriCure當前的估值約爲FY25銷售額的2.7倍，與其小市值MedTech同行相比，後者約爲3.7倍。
以下爲今日6位分析師對$AtriCure (ATRC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
